Selumetinib in Children with Inoperable Plexiform Neurofibromas

BACKGROUND: No approved therapies exist for inoperable plexiform neurofibromas in patients with neurofibromatosis type 1. METHODS: We conducted an open-label, phase 2 trial of selumetinib to determine the objective response rate among patients with plexiform neurofibromas and to assess clinical bene...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:N Engl J Med
Main Authors: Gross, Andrea M., Wolters, Pamela L., Dombi, Eva, Baldwin, Andrea, Whitcomb, Patricia, Fisher, Michael J., Weiss, Brian, Kim, AeRang, Bornhorst, Miriam, Shah, Amish C., Martin, Staci, Roderick, Marie C., Pichard, Dominique C., Carbonell, Amanda, Paul, Scott M., Therrien, Janet, Kapustina, Oxana, Heisey, Kara, Clapp, D. Wade, Zhang, Chi, Peer, Cody J., Figg, William D., Smith, Malcolm, Glod, John, Blakeley, Jaishri O., Steinberg, Seth M., Venzon, David J., Doyle, L. Austin, Widemann, Brigitte C.
Formato: Artigo
Idioma:Inglês
Publicado: 2020
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7305659/
https://ncbi.nlm.nih.gov/pubmed/32187457
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1912735
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares